By Connor Hart

Shares of Emergent Biosolutions fell after the company widened its loss and logged lower revenue during the fourth quarter.

The stock sank 23%, to $8.58, in premarket trading Friday. Through Thursday's close, shares are up 48% over the past year.

The company after Thursday's closing bell posted a loss of $54.6 million, or $1.04 a share, compared with a loss of $31.3 million, or 58 cents a share, a year earlier.

Stripping out one-time items, Emergent reported a loss of 43 cents a share.

Revenue fell to $148.7 million, from $194.7 million in the same quarter last year.

Chief Executive Joe Papa said the company made progress executing on its multi-year turnaround strategy last year, citing improved operating margins, increased cash flow and lower leverage.

Looking forward, the company in 2026 aims to expand its international operations, pursue growth opportunities and remain disciplined on operational efficiencies, he added.

For the current quarter, Emergent guided for revenue of $135 million to $155 million.

For the year, the company forecast a net loss between $10 million and $30 million, or earnings of $25 million to $45 million on an adjusted basis. Revenue is projected to come in between $720 million and $760 million, the midpoint of which is below the $742.9 million in revenue the company posted last year.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

February 27, 2026 06:51 ET (11:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.